Scientific Online Resource System

Annual for Hospital Pharmacy

Biological, biotechnological and biosimilar medicinal products

A. Stoimenova, L. Antonov

Abstract

The current publication reviews the main terms related to biologicals and biotechnology medicinal products. The use of biosimilars is discussed. The main characteristics of the biological medicinal products, use of biotechnology manufacturing methods in the production of medicines as well as the biosimilarity concept are presented. The regulation of biologicals, biotechnology medicines and biosimilars in the EU is reviewed.

Full Text


References

Avidor, Y., Mabjeesh, N. et Matzkin, H. Biotechnology and Drug Discovery: From Bench to Bedside. Southern Medical Journal, 2003, Vol. 96, No.12.

Boehncke, W.H. et Radeke H.H. (Eds.) Biologics in General Medicine, Springer-Verlag Berlin Heidelberg New York, 2007, 190 pp.

Calvo, B. et Zuñiga, L. EU`s New Pharmacovigilance Legislation: Considerations for Biosimilars. Drug Safety. 2014, Vol. 37, pp. 9-18

Chow, S.C. et Ch. Ju. Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013, Vol. 2. No.1, pp. 20-5.

Ciftci, K. Biosimilars or Follow-on Biologics: Scientific and Regulatory Considerations. ICON Insight. 2010, Vol. 18, pp. 1-5

Dalgaard, K., Evers, M. et Santos da Silva, J. Biosimilars seven years on: Where are we and what`s next? Insights into Pharmaceutical and Medical Products. McKinsey & Company, 2012

Dudzinski, D. Reflections on Historical, Scientific, and Legal Issues Relevant to Designing Approval Pathways for Generic Versions of Recombinant Protein - based Therapeutics and Monoclonal Antibodies. Food and Drug Law Journal, 2005, pp. 2-3.

Editorial. Tighter EU rules on pharmacovigilance for biologicals. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012, Vol. 1, No. 2, pp. 567.

EuropaBio. Guide to Biological Medicines. A Focus on Biosimilar Medicines. EuropaBio. [Online] October 26, 2011. via http://www.europabio.org/guide-biological-medicines-focus-biosimilar-medicines.

Fox, A. Biosimilar medicines - New challenges for a new class of medicine. J Biopharm Stat. 2010, Vol. 20, No.1, pp. 3-9.

Gamerman, G.E. Regulation of Biologics Manufacturing: Questioning the Premise. Food and Drug Law Journal, 1994, vol. 49, pp. 218.

Grabowski, H, Cockburn, I. et Long, G. The Market for Follow - on Biologics: How Will it Evolve?`Health Affairs, Vol. 25, No. 5, September/October 2006, p. 1299.

Herrera, S. Biogenerics Standoff, Nature Biotechnology, Vol. 22, No. 11, Nov. 2004, p. 1345.

Horton, L.R. The European Experience With Follow-on Biologics Legislation, Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation, 2008

Kaldre, I. The future of generic biologics: Should the United States `follow-on` the European pathway? Duke Law & Technology Review 2008; 9:5-18

Kingham, R., Klasa, G. et Carver, K.H. Key Regulatory Guidelines for the Development of Biologics in the United States and Europe. In: Biological Drug Products: Development and Strategies, First Edition. Edited by Wei Wang and Manmohan Singh. 2014 John Wiley & Sons, Inc.

McCamish, M. et Woollett, G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012; 91(3): 405-417.

Roger, S.D. et Mikhail, A. Biosimilars: opportunity or cause for concern?. J Pharm Pharm Sci. 2007, Vol. 10, No. 3, pp. 405-10

Schellekens, H., `When biotech proteins go off - patent,` Trends in Biotechnology. 2004, Vol. 22, No. 8, pp. 407.

van Regenmortel, M.H., Boven, K. et Bader, F. Immunogenicity of Biopharmaceuticals: An Example from Erythropoietin. BioPharm International, August 1, 2005, accessed via http://www.biopharminternational.com

European Commission Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products

GaBI Online Generics and Biosimilars Initiative. What happened in biosimilars during 2014 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International. Available from: http://www.gabionline.net/Biosimilars/General/What-happened-in-biosimilars-during-2014

IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets. October 2014

http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_321_2014_Rev01_2014_10.pdf

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000330.jsp &mid=WC0b01ac058002956b#ComparabilityBiosimilarity




DOI: http://dx.doi.org/10.14748/.v1i1.1877

Refbacks

Article Tools
Email this article (Login required)
|